Tarlatamab (AMG-757) is a first-in-class, half-life extended (HLE) bispecific T-cell engager (BiTE) antibody designed for targeted immuno-oncology applications. This therapeutic antibody specifically targets delta-like ligand 3 (DLL3), a protein predominantly expressed in small-cell lung cancer (SCLC) cells, with minimal expression in healthy tissues. Tarlatamab exhibits high binding affinities with dissociation constants (K_Ds) of 0.64 nM for human DLL3 and 0.50 nM for nonhuman primate (NHP) DLL3. Additionally, it shows binding affinities of 14.9 nM and 12 nM for human and NHP CD3, respectively. The selective targeting of DLL3 and the engagement of CD3, a critical component of the T-cell receptor complex, make Tarlatamab a promising candidate for the study and potential treatment of SCLC.
Tarlatamab (AMG-757) is a first-in-class, half-life extended (HLE) bispecific T-cell engager (BiTE) antibody designed for targeted immuno-oncology applications. This therapeutic antibody specifically targets delta-like ligand 3 (DLL3), a protein predominantly expressed in small-cell lung cancer (SCLC) cells, with minimal expression in healthy tissues. Tarlatamab exhibits high binding affinities with dissociation constants (K_Ds) of 0.64 nM for human DLL3 and 0.50 nM for nonhuman primate (NHP) DLL3. Additionally, it shows binding affinities of 14.9 nM and 12 nM for human and NHP CD3, respectively. The selective targeting of DLL3 and the engagement of CD3, a critical component of the T-cell receptor complex, make Tarlatamab a promising candidate for the study and potential treatment of SCLC.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
Please check COA/MSDS for correct molecular weight.
Calculate the dilution required to prepare a stock solution.This equation is commonly abbreviated as: C1V1 = C2V2
Frequently Asked Questions
What are Biosimilar Antibodies?
Biosimilar antibodies are research-grade recombinant antibodies designed to closely resemble approved therapeutic antibodies in terms of amino acid sequence, structural characteristics, and biological activity. These antibodies are generated using recombinant expression technologies and retain the same variable regions as their corresponding reference therapeutics, thereby preserving target specificity and binding affinity. Owing to these properties, biosimilar antibodies serve as reliable and cost-effective research reagents for applications in drug discovery, pharmacological studies, and basic biomedical research.
Research-grade biosimilar antibodies have been successfully expressed and functionally validated against a wide range of widely studied targets. These antibodies can be directly utilized as positive control reagents in drug discovery programs, as well as reference tools for rapid verification of the biological functions of target proteins in biochemical and cellular assays.
